Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy

McParlin, Catherine; O’Donnell, Amy; Robson, Stephen C.; Beyer, Fiona; Moloney, Eoin; Bryant, Andrew; Bradley, Jennifer; Muirhead, Colin R.; Nelson‐Piercy, Catherine; Newbury‐Birch, Dorothy; Norman, Justine; Shaw, Caroline; Simpson, Emma; Swallow, Brian; Yates, Laura; Vale, Luke

doi:10.1001/jama.2016.14337

Cited by 141 publications

(118 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, until recently, there was lack of aggregated evidence on the efficacy of various treatment options for HG. The Cochrane review [6] and systematic review of McParlin et al [25] both concluded that there is little high-quality evidence supporting any intervention for HG treatment and highlighted the need for more high-quality trials and a uniform definition and core outcome set for HG [6, 26]. However, they did emphasize that some antiemetic medication is effective for treating HG.…”

Section: Discussionmentioning

confidence: 99%

Patient Preferences and Experiences in Hyperemesis Gravidarum Treatment: A Qualitative Study

Vliet

Bink

Polman

et al. 2018

Journal of Pregnancy

View full text Add to dashboard Cite

Introduction Hyperemesis gravidarum (HG) medical therapies are currently of limited effect, which creates a larger role for patient preferences in the way HG care is arranged. This is the first study using in-depth interviews to investigate patients' preferences and experiences of HG treatment. Materials and Methods We conducted individual in-depth interviews among women who had been hospitalized for HG in North Holland at least once in the past 4 years. We asked them about their experiences, preferences, and suggestions for improvement regarding the HG treatment they received. The sample size was determined by reaching data saturation. Themes were identified from analysis of the interview transcripts. Results and Discussion 13 women were interviewed. Interviewees emphasized the importance of early recognition of the severity of HG, increasing caregivers' knowledge on HG, early medical intervention, and nasogastric tube feeding. They valued a single room in hospital, discussion of treatment options, more possibilities of home-treatment, psychological support during HG and after childbirth, and more uniform information and policies regarding HG treatment. Conclusion Further research is needed to establish whether the suggestions can lead to more (cost) effective care and improve the course of HG and outcomes for HG patients and their children.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient Preferences and Experiences in Hyperemesis Gravidarum Treatment: A Qualitative Study

Vliet

Bink

Polman

et al. 2018

Journal of Pregnancy

View full text Add to dashboard Cite

show abstract

“…Hyperemesis gravidarum occurs in 0.3%–2.0% of pregnancies; the condition requires treatment because of severe nausea and vomiting in early pregnancy . Generally, the onset of hyperemesis gravidarum is at 4–12 weeks of pregnancy, which is consistent with the timing of fetal organ formation . Thus, medication for hyperemesis gravidarum should be administered with special attention directed toward avoiding adverse neonatal outcomes.…”

Section: Introductionmentioning

confidence: 98%

Safety and effectiveness of Japanese herbal Kampo medicines for treatment of hyperemesis gravidarum

Michihata

Shigemi

Sasabuchi

et al. 2019

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objectives To investigate whether Japanese Kampo medicines, including Sho‐hange‐kabukuryou‐to, Touki‐syakuyaku‐san, and Hange‐kouboku‐to, are safe for fetuses, and whether these medicines reduce hospitalizations and medical costs in pregnant women with hyperemesis gravidarum. Methods We used the Japan Medical Data Center database to extract data for pregnant women (aged ≥19 years) admitted to obstetric clinics or hospitals for delivery between January 1, 2005, and December 31, 2016. Eligible patients were classified into three groups: Kampo medicines for hyperemesis gravidarum, other medicines for hyperemesis gravidarum, and without hyperemesis gravidarum. Safety outcome measures were neonatal outcomes (congenital anomalies, low birthweight, and preterm birth), and effectiveness measures were mother's unplanned hospitalization for hyperemesis gravidarum and total medical costs within 20 weeks of gestation. Results We identified 121 287 eligible mothers. No significant differences in the safety measures were observed among the groups. The Kampo medication group had a significantly lower proportion of mothers with unplanned hospital admission (odds ratio 0.80, 95% confidence interval [CI] 0.69–0.92) and lower total costs (coefficient [US$] 12.8, 95% CI −23.2 to −2.4) than the other medication group. Conclusion Kampo medicines may reduce unplanned admissions and medical costs among pregnant women with hyperemesis gravidarum. UMIN Clinical Trials Registry: R000037298 UMIN000032706.

show abstract

“…A systematic review published in 2016 included data from 35 trials assessed to be at low risk of bias 7. Overall, the quality of evidence was low.…”

Section: Interventions For Managing Nvpmentioning

confidence: 99%

Doxylamine/pyridoxine for nausea and vomiting in pregnancy

2019

DTB

View full text Add to dashboard Cite

Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy

Cited by 141 publications

References 84 publications

Patient Preferences and Experiences in Hyperemesis Gravidarum Treatment: A Qualitative Study

Patient Preferences and Experiences in Hyperemesis Gravidarum Treatment: A Qualitative Study

Safety and effectiveness of Japanese herbal Kampo medicines for treatment of hyperemesis gravidarum

Doxylamine/pyridoxine for nausea and vomiting in pregnancy

Contact Info

Product

Resources

About